Treatment of resistant pemphigus vulgaris with an anti-CD20 monoclonal antibody (Rituximab).
作者： H. L. Cooper , E. Healy , J. M. Theaker , P. S. Friedmann
DOI: 10.1046/J.1365-2230.2003.01283.X
关键词:
摘要: We describe a 54-year-old man with resistant pemphigus vulgaris. Standard therapies had afforded inadequate control and have been associated considerable side-effects. The anti-CD20 monoclonal antibody, Rituximab (MabThera, Roche), was trialled significant benefit. discuss its potential mechanism of action.
core.ac.uk
sci-hub.se 参考文章(10)
ME Reff, K Carner, KS Chambers, PC Chinn, JE Leonard, R Raab, RA Newman, N Hanna, DR Anderson, Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20 Blood. ,vol. 83, pp. 435- 445 ,(1994) , 10.1182/BLOOD.V83.2.435.435
Jean-Claude Bystryn, Diane Jiao, Steven Natow, Treatment of pemphigus with intravenous immunoglobulin. Journal of The American Academy of Dermatology. ,vol. 47, pp. 358- 363 ,(2002) , 10.1067/MJD.2002.122735
Gonzalo V. Gonzalez-Stawinski, Paul B. Yu, Stephanie D. Love, William Parker, R.Duane Davis, Hapten-induced primary and memory humoral responses are inhibited by the infusion of anti-CD20 monoclonal antibody (IDEC-C2B8, Rituximab). Clinical Immunology. ,vol. 98, pp. 175- 179 ,(2001) , 10.1006/CLIM.2000.4980
K. Bhol, K. Natarajan, N. Nagarwalla, A. Mohimen, V. Aoki, A. R. Ahmed, Correlation of peptide specificity and IgG subclass with pathogenic and nonpathogenic autoantibodies in pemphigus vulgaris: a model for autoimmunity Proceedings of the National Academy of Sciences of the United States of America. ,vol. 92, pp. 5239- 5243 ,(1995) , 10.1073/PNAS.92.11.5239
Koji Nishifuji, Masayuki Amagai, Masataka Kuwana, Toshiro Iwasaki, Takeji Nishikawa, Detection of Antigen-Specific B Cells in Patients with Pemphigus Vulgaris by Enzyme-Linked Immunospot Assay: Requirement of T Cell Collaboration for Autoantibody Production Journal of Investigative Dermatology. ,vol. 114, pp. 88- 94 ,(2000) , 10.1046/J.1523-1747.2000.00840.X
DG Maloney, TM Liles, DK Czerwinski, C Waldichuk, J Rosenberg, A Grillo-Lopez, R Levy, Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma Blood. ,vol. 84, pp. 2457- 2466 ,(1994) , 10.1182/BLOOD.V84.8.2457.2457
Mark K Slifka, Rustom Antia, Jason K Whitmire, Rafi Ahmed, None, Humoral immunity due to long-lived plasma cells Immunity. ,vol. 8, pp. 363- 372 ,(1998) , 10.1016/S1074-7613(00)80541-5
Lawrence S. Chan, Carol J. Vanderlugt, Takashi Hashimoto, Takeji Nishikawa, John J. Zone, Martin M. Black, Fenella Wojnarowska, Seth R. Stevens, Mei Chen, Janet A. Fairley, David T. Woodley, Stephen D. Miller, Kenneth B. Gordon, Epitope spreading : Lessons from autoimmune skin diseases Journal of Investigative Dermatology. ,vol. 110, pp. 103- 109 ,(1998) , 10.1046/J.1523-1747.1998.00107.X
K Arzoo, S Sadeghi, HA Liebman, Treatment of refractory antibody mediated autoimmune disorders with an anti-CD20 monoclonal antibody (rituximab) Annals of the Rheumatic Diseases. ,vol. 61, pp. 922- 924 ,(2002) , 10.1136/ARD.61.10.922
Sergio Rutella, Stefan Hohaus, Maria Teresa Voso, Francesco D'Alò, Giuseppe Leone, Mirjam Weis, Raffaella Urbano, Gitta Pantel, Rainer Haas, Rituximab reduces the number of peripheral blood B-cells in vitro mainly by effector cell-mediated mechanisms Haematologica. ,vol. 87, pp. 918- 925 ,(2002)